nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Fludarabine—lymphatic system cancer	0.298	0.514	CrCtD
Regadenoson—Cytarabine—lymphatic system cancer	0.282	0.486	CrCtD
Regadenoson—Adenosine triphosphate—Fludarabine—lymphatic system cancer	0.0254	0.0653	CrCrCtD
Regadenoson—Ribavirin—Fludarabine—lymphatic system cancer	0.0235	0.0605	CrCrCtD
Regadenoson—Ribavirin—Cytarabine—lymphatic system cancer	0.0222	0.0572	CrCrCtD
Regadenoson—S-Adenosylmethionine—Fludarabine—lymphatic system cancer	0.022	0.0565	CrCrCtD
Regadenoson—Clofarabine—Fludarabine—lymphatic system cancer	0.022	0.0565	CrCrCtD
Regadenoson—S-Adenosylmethionine—Cytarabine—lymphatic system cancer	0.0207	0.0533	CrCrCtD
Regadenoson—Clofarabine—Cytarabine—lymphatic system cancer	0.0207	0.0533	CrCrCtD
Regadenoson—Fludarabine—Cytarabine—lymphatic system cancer	0.0195	0.05	CrCrCtD
Regadenoson—Nelarabine—Fludarabine—lymphatic system cancer	0.0194	0.0499	CrCrCtD
Regadenoson—Adenosine monophosphate—Fludarabine—lymphatic system cancer	0.0194	0.0499	CrCrCtD
Regadenoson—Cytarabine—Fludarabine—lymphatic system cancer	0.0184	0.0472	CrCrCtD
Regadenoson—Adenosine monophosphate—Cytarabine—lymphatic system cancer	0.0183	0.0471	CrCrCtD
Regadenoson—Nelarabine—Cytarabine—lymphatic system cancer	0.0183	0.0471	CrCrCtD
Regadenoson—Adenosine—Fludarabine—lymphatic system cancer	0.0174	0.0448	CrCrCtD
Regadenoson—Vidarabine—Fludarabine—lymphatic system cancer	0.0174	0.0448	CrCrCtD
Regadenoson—Cladribine—Fludarabine—lymphatic system cancer	0.0174	0.0448	CrCrCtD
Regadenoson—Azacitidine—Fludarabine—lymphatic system cancer	0.0174	0.0448	CrCrCtD
Regadenoson—Azacitidine—Cytarabine—lymphatic system cancer	0.0165	0.0424	CrCrCtD
Regadenoson—Adenosine—Cytarabine—lymphatic system cancer	0.0165	0.0424	CrCrCtD
Regadenoson—Vidarabine—Cytarabine—lymphatic system cancer	0.0165	0.0424	CrCrCtD
Regadenoson—Adenosine triphosphate—ALK—lymphatic system cancer	0.00114	1	CrCbGaD
Regadenoson—Injection site pain—Carmustine—lymphatic system cancer	0.000298	0.00985	CcSEcCtD
Regadenoson—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.000281	0.00931	CcSEcCtD
Regadenoson—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.000281	0.0093	CcSEcCtD
Regadenoson—Tinnitus—Mechlorethamine—lymphatic system cancer	0.000274	0.00908	CcSEcCtD
Regadenoson—Wheezing—Bleomycin—lymphatic system cancer	0.00027	0.00895	CcSEcCtD
Regadenoson—Bronchospasm—Teniposide—lymphatic system cancer	0.000267	0.00882	CcSEcCtD
Regadenoson—Musculoskeletal pain—Vincristine—lymphatic system cancer	0.000235	0.00777	CcSEcCtD
Regadenoson—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.000235	0.00776	CcSEcCtD
Regadenoson—Angina pectoris—Fludarabine—lymphatic system cancer	0.000232	0.00768	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.000217	0.00717	CcSEcCtD
Regadenoson—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.000209	0.00693	CcSEcCtD
Regadenoson—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.000209	0.00692	CcSEcCtD
Regadenoson—Renal failure—Fludarabine—lymphatic system cancer	0.000209	0.00691	CcSEcCtD
Regadenoson—Myocardial infarction—Fludarabine—lymphatic system cancer	0.000208	0.00689	CcSEcCtD
Regadenoson—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.000206	0.00682	CcSEcCtD
Regadenoson—Skin disorder—Mechlorethamine—lymphatic system cancer	0.000203	0.00672	CcSEcCtD
Regadenoson—Flushing—Teniposide—lymphatic system cancer	0.000201	0.00666	CcSEcCtD
Regadenoson—Eye pain—Carmustine—lymphatic system cancer	0.000195	0.00647	CcSEcCtD
Regadenoson—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00019	0.00628	CcSEcCtD
Regadenoson—Bronchospasm—Bleomycin—lymphatic system cancer	0.000172	0.00568	CcSEcCtD
Regadenoson—Pain in extremity—Vincristine—lymphatic system cancer	0.000168	0.00557	CcSEcCtD
Regadenoson—Hypertension—Teniposide—lymphatic system cancer	0.000163	0.0054	CcSEcCtD
Regadenoson—Chest pain—Teniposide—lymphatic system cancer	0.000161	0.00532	CcSEcCtD
Regadenoson—Cardiac arrest—Vincristine—lymphatic system cancer	0.00016	0.0053	CcSEcCtD
Regadenoson—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000154	0.0051	CcSEcCtD
Regadenoson—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.000154	0.0051	CcSEcCtD
Regadenoson—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.000154	0.00508	CcSEcCtD
Regadenoson—Myocardial infarction—Bleomycin—lymphatic system cancer	0.000153	0.00505	CcSEcCtD
Regadenoson—Tachycardia—Teniposide—lymphatic system cancer	0.00015	0.00498	CcSEcCtD
Regadenoson—Malaise—Fludarabine—lymphatic system cancer	0.00015	0.00495	CcSEcCtD
Regadenoson—Hyperhidrosis—Teniposide—lymphatic system cancer	0.000149	0.00493	CcSEcCtD
Regadenoson—Cough—Fludarabine—lymphatic system cancer	0.000145	0.00479	CcSEcCtD
Regadenoson—Hypotension—Teniposide—lymphatic system cancer	0.000144	0.00477	CcSEcCtD
Regadenoson—Convulsion—Fludarabine—lymphatic system cancer	0.000144	0.00476	CcSEcCtD
Regadenoson—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000143	0.00473	CcSEcCtD
Regadenoson—Myalgia—Fludarabine—lymphatic system cancer	0.000141	0.00468	CcSEcCtD
Regadenoson—Arthralgia—Fludarabine—lymphatic system cancer	0.000141	0.00468	CcSEcCtD
Regadenoson—Discomfort—Fludarabine—lymphatic system cancer	0.00014	0.00462	CcSEcCtD
Regadenoson—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.000139	0.0046	CcSEcCtD
Regadenoson—Dyspnoea—Teniposide—lymphatic system cancer	0.000137	0.00455	CcSEcCtD
Regadenoson—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000135	0.00448	CcSEcCtD
Regadenoson—Renal failure—Carmustine—lymphatic system cancer	0.000134	0.00442	CcSEcCtD
Regadenoson—Vomiting—Mechlorethamine—lymphatic system cancer	0.000133	0.0044	CcSEcCtD
Regadenoson—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000133	0.0044	CcSEcCtD
Regadenoson—Rash—Mechlorethamine—lymphatic system cancer	0.000132	0.00436	CcSEcCtD
Regadenoson—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000132	0.00436	CcSEcCtD
Regadenoson—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000131	0.00433	CcSEcCtD
Regadenoson—Flushing—Bleomycin—lymphatic system cancer	0.00013	0.00429	CcSEcCtD
Regadenoson—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000128	0.00423	CcSEcCtD
Regadenoson—Myocardial infarction—Vincristine—lymphatic system cancer	0.000127	0.00421	CcSEcCtD
Regadenoson—Feeling abnormal—Teniposide—lymphatic system cancer	0.000127	0.0042	CcSEcCtD
Regadenoson—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000126	0.00417	CcSEcCtD
Regadenoson—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000125	0.00412	CcSEcCtD
Regadenoson—Renal failure—Mitoxantrone—lymphatic system cancer	0.000124	0.00411	CcSEcCtD
Regadenoson—Nausea—Mechlorethamine—lymphatic system cancer	0.000124	0.00411	CcSEcCtD
Regadenoson—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000124	0.0041	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000123	0.00408	CcSEcCtD
Regadenoson—Urticaria—Teniposide—lymphatic system cancer	0.000122	0.00405	CcSEcCtD
Regadenoson—Abdominal pain—Teniposide—lymphatic system cancer	0.000122	0.00403	CcSEcCtD
Regadenoson—Erythema—Bleomycin—lymphatic system cancer	0.000122	0.00403	CcSEcCtD
Regadenoson—Paraesthesia—Fludarabine—lymphatic system cancer	0.000122	0.00402	CcSEcCtD
Regadenoson—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000121	0.00402	CcSEcCtD
Regadenoson—Dyspnoea—Fludarabine—lymphatic system cancer	0.000121	0.004	CcSEcCtD
Regadenoson—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00012	0.00397	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000117	0.00387	CcSEcCtD
Regadenoson—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000116	0.00384	CcSEcCtD
Regadenoson—Pain—Fludarabine—lymphatic system cancer	0.000116	0.00383	CcSEcCtD
Regadenoson—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000116	0.00382	CcSEcCtD
Regadenoson—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000115	0.00379	CcSEcCtD
Regadenoson—Eye disorder—Carmustine—lymphatic system cancer	0.000114	0.00377	CcSEcCtD
Regadenoson—Hypersensitivity—Teniposide—lymphatic system cancer	0.000114	0.00376	CcSEcCtD
Regadenoson—Flushing—Carmustine—lymphatic system cancer	0.000113	0.00375	CcSEcCtD
Regadenoson—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000113	0.00374	CcSEcCtD
Regadenoson—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000112	0.00369	CcSEcCtD
Regadenoson—Asthenia—Teniposide—lymphatic system cancer	0.000111	0.00366	CcSEcCtD
Regadenoson—Malaise—Bleomycin—lymphatic system cancer	0.00011	0.00363	CcSEcCtD
Regadenoson—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000109	0.0036	CcSEcCtD
Regadenoson—Cardiac disorder—Vincristine—lymphatic system cancer	0.000108	0.00358	CcSEcCtD
Regadenoson—Mental disorder—Carmustine—lymphatic system cancer	0.000107	0.00354	CcSEcCtD
Regadenoson—Erythema—Carmustine—lymphatic system cancer	0.000106	0.00351	CcSEcCtD
Regadenoson—Cough—Bleomycin—lymphatic system cancer	0.000106	0.00351	CcSEcCtD
Regadenoson—Angiopathy—Vincristine—lymphatic system cancer	0.000106	0.0035	CcSEcCtD
Regadenoson—Diarrhoea—Teniposide—lymphatic system cancer	0.000105	0.00349	CcSEcCtD
Regadenoson—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000105	0.00347	CcSEcCtD
Regadenoson—Chest pain—Bleomycin—lymphatic system cancer	0.000104	0.00343	CcSEcCtD
Regadenoson—Myalgia—Bleomycin—lymphatic system cancer	0.000104	0.00343	CcSEcCtD
Regadenoson—Discomfort—Bleomycin—lymphatic system cancer	0.000102	0.00339	CcSEcCtD
Regadenoson—Mental disorder—Vincristine—lymphatic system cancer	0.000102	0.00338	CcSEcCtD
Regadenoson—Vision blurred—Carmustine—lymphatic system cancer	0.0001	0.00331	CcSEcCtD
Regadenoson—Hypersensitivity—Fludarabine—lymphatic system cancer	9.98e-05	0.0033	CcSEcCtD
Regadenoson—Tremor—Carmustine—lymphatic system cancer	9.96e-05	0.00329	CcSEcCtD
Regadenoson—Anaphylactic shock—Bleomycin—lymphatic system cancer	9.93e-05	0.00329	CcSEcCtD
Regadenoson—Erythema—Mitoxantrone—lymphatic system cancer	9.88e-05	0.00327	CcSEcCtD
Regadenoson—Vomiting—Teniposide—lymphatic system cancer	9.8e-05	0.00324	CcSEcCtD
Regadenoson—Asthenia—Fludarabine—lymphatic system cancer	9.72e-05	0.00322	CcSEcCtD
Regadenoson—Rash—Teniposide—lymphatic system cancer	9.72e-05	0.00322	CcSEcCtD
Regadenoson—Dermatitis—Teniposide—lymphatic system cancer	9.71e-05	0.00321	CcSEcCtD
Regadenoson—Dysgeusia—Mitoxantrone—lymphatic system cancer	9.67e-05	0.0032	CcSEcCtD
Regadenoson—Headache—Teniposide—lymphatic system cancer	9.66e-05	0.00319	CcSEcCtD
Regadenoson—Vision blurred—Mitoxantrone—lymphatic system cancer	9.31e-05	0.00308	CcSEcCtD
Regadenoson—Hypotension—Bleomycin—lymphatic system cancer	9.28e-05	0.00307	CcSEcCtD
Regadenoson—Diarrhoea—Fludarabine—lymphatic system cancer	9.27e-05	0.00307	CcSEcCtD
Regadenoson—Convulsion—Carmustine—lymphatic system cancer	9.21e-05	0.00305	CcSEcCtD
Regadenoson—Hypertension—Carmustine—lymphatic system cancer	9.17e-05	0.00303	CcSEcCtD
Regadenoson—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	9.17e-05	0.00303	CcSEcCtD
Regadenoson—Nausea—Teniposide—lymphatic system cancer	9.16e-05	0.00303	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	9.05e-05	0.00299	CcSEcCtD
Regadenoson—Myalgia—Carmustine—lymphatic system cancer	9.05e-05	0.00299	CcSEcCtD
Regadenoson—Chest pain—Carmustine—lymphatic system cancer	9.05e-05	0.00299	CcSEcCtD
Regadenoson—Anxiety—Carmustine—lymphatic system cancer	9.01e-05	0.00298	CcSEcCtD
Regadenoson—Paraesthesia—Bleomycin—lymphatic system cancer	8.92e-05	0.00295	CcSEcCtD
Regadenoson—Malaise—Mitoxantrone—lymphatic system cancer	8.91e-05	0.00295	CcSEcCtD
Regadenoson—Dyspnoea—Bleomycin—lymphatic system cancer	8.86e-05	0.00293	CcSEcCtD
Regadenoson—Convulsion—Vincristine—lymphatic system cancer	8.79e-05	0.00291	CcSEcCtD
Regadenoson—Hypertension—Vincristine—lymphatic system cancer	8.76e-05	0.0029	CcSEcCtD
Regadenoson—Myalgia—Vincristine—lymphatic system cancer	8.64e-05	0.00286	CcSEcCtD
Regadenoson—Cough—Mitoxantrone—lymphatic system cancer	8.62e-05	0.00285	CcSEcCtD
Regadenoson—Vomiting—Fludarabine—lymphatic system cancer	8.62e-05	0.00285	CcSEcCtD
Regadenoson—Convulsion—Mitoxantrone—lymphatic system cancer	8.56e-05	0.00283	CcSEcCtD
Regadenoson—Rash—Fludarabine—lymphatic system cancer	8.54e-05	0.00283	CcSEcCtD
Regadenoson—Dermatitis—Fludarabine—lymphatic system cancer	8.54e-05	0.00282	CcSEcCtD
Regadenoson—Hypertension—Mitoxantrone—lymphatic system cancer	8.53e-05	0.00282	CcSEcCtD
Regadenoson—Pain—Bleomycin—lymphatic system cancer	8.5e-05	0.00281	CcSEcCtD
Regadenoson—Headache—Fludarabine—lymphatic system cancer	8.49e-05	0.00281	CcSEcCtD
Regadenoson—Tachycardia—Carmustine—lymphatic system cancer	8.46e-05	0.0028	CcSEcCtD
Regadenoson—Chest pain—Mitoxantrone—lymphatic system cancer	8.41e-05	0.00278	CcSEcCtD
Regadenoson—Myalgia—Mitoxantrone—lymphatic system cancer	8.41e-05	0.00278	CcSEcCtD
Regadenoson—Arthralgia—Mitoxantrone—lymphatic system cancer	8.41e-05	0.00278	CcSEcCtD
Regadenoson—Anxiety—Mitoxantrone—lymphatic system cancer	8.38e-05	0.00277	CcSEcCtD
Regadenoson—Cerebrovascular accident—Methotrexate—lymphatic system cancer	8.34e-05	0.00276	CcSEcCtD
Regadenoson—Discomfort—Mitoxantrone—lymphatic system cancer	8.31e-05	0.00275	CcSEcCtD
Regadenoson—Anaphylactic shock—Vincristine—lymphatic system cancer	8.28e-05	0.00274	CcSEcCtD
Regadenoson—Feeling abnormal—Bleomycin—lymphatic system cancer	8.19e-05	0.00271	CcSEcCtD
Regadenoson—Nervous system disorder—Vincristine—lymphatic system cancer	8.12e-05	0.00269	CcSEcCtD
Regadenoson—Hypotension—Carmustine—lymphatic system cancer	8.1e-05	0.00268	CcSEcCtD
Regadenoson—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	8.06e-05	0.00267	CcSEcCtD
Regadenoson—Nausea—Fludarabine—lymphatic system cancer	8.05e-05	0.00266	CcSEcCtD
Regadenoson—Hyperhidrosis—Vincristine—lymphatic system cancer	8e-05	0.00265	CcSEcCtD
Regadenoson—Shock—Mitoxantrone—lymphatic system cancer	7.93e-05	0.00262	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	7.9e-05	0.00261	CcSEcCtD
Regadenoson—Urticaria—Bleomycin—lymphatic system cancer	7.89e-05	0.00261	CcSEcCtD
Regadenoson—Tachycardia—Mitoxantrone—lymphatic system cancer	7.87e-05	0.0026	CcSEcCtD
Regadenoson—Insomnia—Carmustine—lymphatic system cancer	7.84e-05	0.00259	CcSEcCtD
Regadenoson—Skin disorder—Mitoxantrone—lymphatic system cancer	7.83e-05	0.00259	CcSEcCtD
Regadenoson—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	7.79e-05	0.00258	CcSEcCtD
Regadenoson—Paraesthesia—Carmustine—lymphatic system cancer	7.79e-05	0.00258	CcSEcCtD
Regadenoson—Hypotension—Vincristine—lymphatic system cancer	7.74e-05	0.00256	CcSEcCtD
Regadenoson—Dyspnoea—Carmustine—lymphatic system cancer	7.73e-05	0.00256	CcSEcCtD
Regadenoson—Somnolence—Carmustine—lymphatic system cancer	7.71e-05	0.00255	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	7.54e-05	0.00249	CcSEcCtD
Regadenoson—Hypotension—Mitoxantrone—lymphatic system cancer	7.53e-05	0.00249	CcSEcCtD
Regadenoson—Insomnia—Vincristine—lymphatic system cancer	7.49e-05	0.00248	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Carmustine—lymphatic system cancer	7.49e-05	0.00248	CcSEcCtD
Regadenoson—Paraesthesia—Vincristine—lymphatic system cancer	7.43e-05	0.00246	CcSEcCtD
Regadenoson—Pain—Carmustine—lymphatic system cancer	7.42e-05	0.00245	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	7.35e-05	0.00243	CcSEcCtD
Regadenoson—Hypersensitivity—Bleomycin—lymphatic system cancer	7.32e-05	0.00242	CcSEcCtD
Regadenoson—Paraesthesia—Mitoxantrone—lymphatic system cancer	7.24e-05	0.00239	CcSEcCtD
Regadenoson—Dyspnoea—Mitoxantrone—lymphatic system cancer	7.19e-05	0.00238	CcSEcCtD
Regadenoson—Somnolence—Mitoxantrone—lymphatic system cancer	7.17e-05	0.00237	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Vincristine—lymphatic system cancer	7.15e-05	0.00236	CcSEcCtD
Regadenoson—Feeling abnormal—Carmustine—lymphatic system cancer	7.15e-05	0.00236	CcSEcCtD
Regadenoson—Asthenia—Bleomycin—lymphatic system cancer	7.13e-05	0.00236	CcSEcCtD
Regadenoson—Gastrointestinal pain—Carmustine—lymphatic system cancer	7.09e-05	0.00235	CcSEcCtD
Regadenoson—Pain—Vincristine—lymphatic system cancer	7.08e-05	0.00234	CcSEcCtD
Regadenoson—Asthma—Methotrexate—lymphatic system cancer	7.06e-05	0.00234	CcSEcCtD
Regadenoson—Pain—Mitoxantrone—lymphatic system cancer	6.89e-05	0.00228	CcSEcCtD
Regadenoson—Abdominal pain—Carmustine—lymphatic system cancer	6.86e-05	0.00227	CcSEcCtD
Regadenoson—Abdominal discomfort—Methotrexate—lymphatic system cancer	6.77e-05	0.00224	CcSEcCtD
Regadenoson—Gastrointestinal pain—Vincristine—lymphatic system cancer	6.77e-05	0.00224	CcSEcCtD
Regadenoson—Feeling abnormal—Mitoxantrone—lymphatic system cancer	6.64e-05	0.0022	CcSEcCtD
Regadenoson—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	6.59e-05	0.00218	CcSEcCtD
Regadenoson—Abdominal pain—Vincristine—lymphatic system cancer	6.54e-05	0.00216	CcSEcCtD
Regadenoson—Urticaria—Mitoxantrone—lymphatic system cancer	6.4e-05	0.00212	CcSEcCtD
Regadenoson—Hypersensitivity—Carmustine—lymphatic system cancer	6.39e-05	0.00211	CcSEcCtD
Regadenoson—Abdominal pain—Mitoxantrone—lymphatic system cancer	6.37e-05	0.00211	CcSEcCtD
Regadenoson—Vomiting—Bleomycin—lymphatic system cancer	6.32e-05	0.00209	CcSEcCtD
Regadenoson—Rash—Bleomycin—lymphatic system cancer	6.26e-05	0.00207	CcSEcCtD
Regadenoson—Dermatitis—Bleomycin—lymphatic system cancer	6.26e-05	0.00207	CcSEcCtD
Regadenoson—Asthenia—Carmustine—lymphatic system cancer	6.22e-05	0.00206	CcSEcCtD
Regadenoson—Renal failure—Methotrexate—lymphatic system cancer	6.19e-05	0.00205	CcSEcCtD
Regadenoson—Hypersensitivity—Vincristine—lymphatic system cancer	6.1e-05	0.00202	CcSEcCtD
Regadenoson—Hypersensitivity—Mitoxantrone—lymphatic system cancer	5.94e-05	0.00196	CcSEcCtD
Regadenoson—Asthenia—Vincristine—lymphatic system cancer	5.94e-05	0.00196	CcSEcCtD
Regadenoson—Diarrhoea—Carmustine—lymphatic system cancer	5.93e-05	0.00196	CcSEcCtD
Regadenoson—Nausea—Bleomycin—lymphatic system cancer	5.9e-05	0.00195	CcSEcCtD
Regadenoson—Asthenia—Mitoxantrone—lymphatic system cancer	5.78e-05	0.00191	CcSEcCtD
Regadenoson—Dizziness—Carmustine—lymphatic system cancer	5.73e-05	0.0019	CcSEcCtD
Regadenoson—Diarrhoea—Vincristine—lymphatic system cancer	5.66e-05	0.00187	CcSEcCtD
Regadenoson—Diarrhoea—Mitoxantrone—lymphatic system cancer	5.52e-05	0.00182	CcSEcCtD
Regadenoson—Vomiting—Carmustine—lymphatic system cancer	5.51e-05	0.00182	CcSEcCtD
Regadenoson—Dizziness—Vincristine—lymphatic system cancer	5.47e-05	0.00181	CcSEcCtD
Regadenoson—Rash—Carmustine—lymphatic system cancer	5.47e-05	0.00181	CcSEcCtD
Regadenoson—Dermatitis—Carmustine—lymphatic system cancer	5.46e-05	0.00181	CcSEcCtD
Regadenoson—Headache—Carmustine—lymphatic system cancer	5.43e-05	0.0018	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—lymphatic system cancer	5.28e-05	0.00175	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—lymphatic system cancer	5.27e-05	0.00174	CcSEcCtD
Regadenoson—Vomiting—Vincristine—lymphatic system cancer	5.26e-05	0.00174	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—lymphatic system cancer	5.25e-05	0.00174	CcSEcCtD
Regadenoson—Rash—Vincristine—lymphatic system cancer	5.22e-05	0.00173	CcSEcCtD
Regadenoson—Dermatitis—Vincristine—lymphatic system cancer	5.21e-05	0.00173	CcSEcCtD
Regadenoson—Headache—Vincristine—lymphatic system cancer	5.19e-05	0.00172	CcSEcCtD
Regadenoson—Nausea—Carmustine—lymphatic system cancer	5.15e-05	0.0017	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—lymphatic system cancer	5.13e-05	0.0017	CcSEcCtD
Regadenoson—Vomiting—Mitoxantrone—lymphatic system cancer	5.13e-05	0.0017	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—lymphatic system cancer	5.11e-05	0.00169	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—lymphatic system cancer	5.1e-05	0.00169	CcSEcCtD
Regadenoson—Rash—Mitoxantrone—lymphatic system cancer	5.08e-05	0.00168	CcSEcCtD
Regadenoson—Dermatitis—Mitoxantrone—lymphatic system cancer	5.08e-05	0.00168	CcSEcCtD
Regadenoson—Headache—Mitoxantrone—lymphatic system cancer	5.05e-05	0.00167	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—lymphatic system cancer	4.95e-05	0.00164	CcSEcCtD
Regadenoson—Erythema—Methotrexate—lymphatic system cancer	4.92e-05	0.00163	CcSEcCtD
Regadenoson—Nausea—Vincristine—lymphatic system cancer	4.92e-05	0.00163	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—lymphatic system cancer	4.82e-05	0.00159	CcSEcCtD
Regadenoson—Nausea—Mitoxantrone—lymphatic system cancer	4.79e-05	0.00158	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—lymphatic system cancer	4.64e-05	0.00153	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—lymphatic system cancer	4.57e-05	0.00151	CcSEcCtD
Regadenoson—Malaise—Methotrexate—lymphatic system cancer	4.44e-05	0.00147	CcSEcCtD
Regadenoson—Cough—Methotrexate—lymphatic system cancer	4.29e-05	0.00142	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—lymphatic system cancer	4.26e-05	0.00141	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—lymphatic system cancer	4.19e-05	0.00139	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—lymphatic system cancer	4.19e-05	0.00139	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—lymphatic system cancer	4.19e-05	0.00139	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	4.16e-05	0.00138	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—lymphatic system cancer	4.14e-05	0.00137	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—lymphatic system cancer	4.02e-05	0.00133	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—lymphatic system cancer	3.94e-05	0.0013	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—lymphatic system cancer	3.9e-05	0.00129	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—lymphatic system cancer	3.88e-05	0.00128	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—lymphatic system cancer	3.75e-05	0.00124	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	3.66e-05	0.00121	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—lymphatic system cancer	3.63e-05	0.0012	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—lymphatic system cancer	3.61e-05	0.00119	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—lymphatic system cancer	3.58e-05	0.00118	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—lymphatic system cancer	3.57e-05	0.00118	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	3.47e-05	0.00115	CcSEcCtD
Regadenoson—Pain—Methotrexate—lymphatic system cancer	3.43e-05	0.00114	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—lymphatic system cancer	3.31e-05	0.00109	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—lymphatic system cancer	3.28e-05	0.00109	CcSEcCtD
Regadenoson—Urticaria—Methotrexate—lymphatic system cancer	3.19e-05	0.00106	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—lymphatic system cancer	3.18e-05	0.00105	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—lymphatic system cancer	2.96e-05	0.000979	CcSEcCtD
Regadenoson—Asthenia—Methotrexate—lymphatic system cancer	2.88e-05	0.000953	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—lymphatic system cancer	2.75e-05	0.000909	CcSEcCtD
Regadenoson—Dizziness—Methotrexate—lymphatic system cancer	2.66e-05	0.000879	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—lymphatic system cancer	2.55e-05	0.000845	CcSEcCtD
Regadenoson—Rash—Methotrexate—lymphatic system cancer	2.53e-05	0.000838	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—lymphatic system cancer	2.53e-05	0.000837	CcSEcCtD
Regadenoson—Headache—Methotrexate—lymphatic system cancer	2.52e-05	0.000832	CcSEcCtD
Regadenoson—Nausea—Methotrexate—lymphatic system cancer	2.39e-05	0.000789	CcSEcCtD
